140 related articles for article (PubMed ID: 22894930)
1. Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Wang M; Halasi M; Kabirov K; Banerjee A; Landolfi J; Lyubimov AV; Gartel AL
Cell Cycle; 2012 Sep; 11(18):3370-2. PubMed ID: 22894930
[TBL] [Abstract][Full Text] [Related]
2. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Pandit B; Gartel AL
PLoS One; 2011 Feb; 6(2):e17110. PubMed ID: 21365012
[TBL] [Abstract][Full Text] [Related]
3. Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Wang M; Gartel AL
Cancer Biol Ther; 2012 Feb; 13(3):184-9. PubMed ID: 22353937
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
Saeki I; Terai S; Fujisawa K; Takami T; Yamamoto N; Matsumoto T; Hirose Y; Murata Y; Yamasaki T; Sakaida I
J Gastroenterol; 2013 Jun; 48(6):738-50. PubMed ID: 23011081
[TBL] [Abstract][Full Text] [Related]
5. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Pandit B; Gartel AL
Prostate; 2010 Jun; 70(8):825-33. PubMed ID: 20058240
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
7. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
9. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
[TBL] [Abstract][Full Text] [Related]
10. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Spratlin JL; Pitts TM; Kulikowski GN; Morelli MP; Tentler JJ; Serkova NJ; Eckhardt SG
Anticancer Res; 2011 Apr; 31(4):1093-103. PubMed ID: 21508352
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
13. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
[TBL] [Abstract][Full Text] [Related]
15. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
[TBL] [Abstract][Full Text] [Related]
16. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
Brüning A; Burger P; Vogel M; Rahmeh M; Friese K; Lenhard M; Burges A
Invest New Drugs; 2009 Dec; 27(6):543-51. PubMed ID: 19039521
[TBL] [Abstract][Full Text] [Related]
18. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Kim GP; Mahoney MR; Szydlo D; Mok TS; Marshke R; Holen K; Picus J; Boyer M; Pitot HC; Rubin J; Philip PA; Nowak A; Wright JJ; Erlichman C
Invest New Drugs; 2012 Feb; 30(1):387-94. PubMed ID: 20839030
[TBL] [Abstract][Full Text] [Related]
19. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Edelman MJ
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
[TBL] [Abstract][Full Text] [Related]
20. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]